Cambridge Investment Research Advisors Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 331,471 shares of the company’s stock after purchasing an additional 3,676 shares during the period. Johnson & Johnson accounts for 0.6% of Cambridge Investment Research Advisors Inc.’s investment portfolio, making the stock its 26th biggest position. Cambridge Investment Research Advisors Inc.’s holdings in Johnson & Johnson were worth $43,094,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares during the period. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares during the period. Bank of New York Mellon Corp grew its position in Johnson & Johnson by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after acquiring an additional 130,437 shares during the period. FMR LLC grew its position in Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after acquiring an additional 1,509,745 shares during the period. Finally, Capital World Investors grew its position in Johnson & Johnson by 4.1% during the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after acquiring an additional 1,050,000 shares during the period. 66.38% of the stock is owned by institutional investors and hedge funds.
In related news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.19% of the company’s stock.
A number of equities research analysts have issued reports on the company. Citigroup lowered their price target on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a research report on Tuesday, February 27th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a research report on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Jefferies Group set a $165.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, Stifel Nicolaus boosted their price target on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and an average target price of $146.26.
Johnson & Johnson (JNJ) traded up $3.02 during trading hours on Thursday, hitting $132.06. The company had a trading volume of 6,419,042 shares, compared to its average volume of 8,990,000. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The firm has a market capitalization of $354,780.00, a PE ratio of 24.32, a price-to-earnings-growth ratio of 2.10 and a beta of 0.77.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The company’s revenue was up 11.5% compared to the same quarter last year. equities research analysts expect that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 61.88%.
TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2018/03/09/johnson-johnson-jnj-stake-increased-by-cambridge-investment-research-advisors-inc.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.